Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many and what proportion of patients who were moved from hospitals to (a) care and (b) nursing homes subsequently died of (i) covid-19 and (ii) other causes within (A) 7, (B) 14, (C) 28, (D) 56 and (E) 112 days of being moved.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The information requested is not held centrally.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients were moved from hospitals to (a) care and (b) nursing homes to create space for anticipated covid-19 patients in England and Wales in (i) March and (ii) April 2020.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The information requested is not held centrally.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, (a) with reference to NICE guideline NG163, published 3 April 2020, by what process that guideline was commissioned, (b) by what processes the NHS decided to procure Midazolam for use in patient care, including end-of-life care and (c) by what process the NHS decided on the quantity of Midazolam it would procure in each of the last four years.
Answered by Will Quince
The National Institute of Health and Care Excellence’s (NICE) guideline NG163 published in 2020 was commissioned in accordance with an established agreement between NHS England and NICE. The focus at that time was given to providing rapid guidance on the management of affected patients with COVID-19. A number of NICE’s COVID-19 rapid guidelines were incorporated into a single guideline for the management of COVID-19 in children and adults (NG191).
During the pandemic there was an increase in demand for, and consequently in the United Kingdom’s purchase of a number of medicines, including midazolam, to support the care of COVID-19 patients in intensive care and at the end of life. National Health Service purchasing decisions are made by individual trusts against national procurement frameworks. Volumes are calculated based on their forecast consumption.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what budget provision his Department has made for costs associated with vaccine harms in the next five years.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Vaccine Damage Payment Scheme amount included in the Annual Report and Accounts, was £9,889,743 as of 31 March 2022. The information can be found in ‘Note 16 Provisions for liabilities and charges’ on page 353. The £9,889,743 is contained in the ‘other’ value of £4,078,443,000. As the amount is not material to the accounts, it was contained in the ‘other’ category with other provisions.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department holds data on the vaccine status of people who died after 31 May 2022.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The UK Health Security Agency (UKHSA) does hold data on the vaccine status of people who died after 31 May 2022.
UKHSA uses the data on the vaccination status of people who have died to produce monthly COVID-19 Vaccine Surveillance reports which can be found at the following link:
https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
This covers an extensive range of measures of vaccine effectiveness, including demonstrating effectiveness against infection, transmission, hospitalisation and mortality.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many and what proportion of clinical NHS staff have received a covid-19 booster vaccination in the most recent period for which data is available.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The United Kingdom Health Security Agency publish monthly reports on seasonal influenza and COVID-19 vaccine uptake in frontline healthcare workers. Data published to the end of November 2022 showed that in 165 NHS trusts providing a return, 338,602 frontline healthcare workers had had a COVID-19 vaccine since 1 September 2022, an uptake of 36.3%.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has had recent discussions with (a) the National Institute for Health and Care Excellence and (b) clinical commissioning groups on the rollout of Libre Two sensors to manage diabetes.
Answered by Robert Jenrick
There have been no recent discussions. The National Institute for Health and Care Excellence updated its guidance on real-time and intermittently scanned continuous glucose monitoring, such as FreeStyle Libre 2 sensors for eligible patients. The newly established integrated care boards will take this guidance into account in commissioning services for local populations.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with industry groups on the sustainability of community pharmacies.
Answered by Will Quince
The Community Pharmacy Contractual Framework five-year deal commits £2.592 billion in each financial year between 2019 and 2024 for community pharmacy. On 22 September 2022, following discussions between the Department, NHS England and the Pharmaceutical Services Negotiating Committee, which represents pharmacy contractors in England, we announced an agreement for the remaining years of the Framework.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much her Department has spent commissioning research into problem gambling in each of the last five years; and whether it is her policy that gambling harms are a public health issue.
Answered by Caroline Johnson
We are committed to tackling gambling-related harms through a public health approach, recognising the potential impacts on individuals, their families, close associates and society. The Department funds research through the National Institute for Health and Care Research (NIHR). The following table shows the funding allocated for research into problem gambling through the NIHR’s research programmes in each of the last five years.
2017/18 | £0.00 |
2018/19 | £0.00 |
2019/20 | £97,535.81 |
2020/21 | £121,439.68 |
2021/22 | £695,254.73 |
In 2019, the former Public Health England conducted an evidence review of gambling-related harms. The cost of research commissioned through this review was £8,000.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the benefits of green spaces and gardening to mental and physical health and what policies the Government is pursuing to ensure those benefits can be realised by people without access to green spaces.
Answered by Maggie Throup
An evidence review of the health effects of access to greenspace, including gardening was published by Public Health England in 2020. It found evidence that exposure to greenspaces can promote and protect good health and aid in recovery from illness and help with managing poor mental and physical health. The evidence review is available at the following link:
The Government’s 25 Year Environment Plan includes specific measures such a cross-Government project on tackling mental ill-health through green social prescribing and a national framework of green infrastructure standards to ensure new developments include accessible green spaces and areas with little or no green space can be improved for the benefit of the community. The Plan is available at the following link: